• LPG-1 medications have gained popularity over the last few Years for Aiding Weight Loss.
  • Tirzepatide IS Available Through Both The Type 2 Diabetes Medication Mounjaro and Weight-Loss Medication Zepbound.
  • A New Study Feded By Eli Lilly Reports That People Without Diabetes Can Loses Up To 13% of Their Starting Weight In 6 Months Using Tirzepatide.
  • The Study used Mounjaro, which is not yet approved spectify for Weight Management.

Over The Last Few Years, There have been an increase in the Use of Glucagon-Like Peptide-1 recipient Agonists (LPG-1 agonists) for Weight Loss.

Originally Designed as A Medication for Type 2 Diabetes, LPG-1 Medications Like Mounjaro (Tirzepatide) and Ozempic (Semaglutide) Have Been used off-Label to Help People Lose Weight.

In November 2023, The Food and Drug Administration (FDA) Approved One LPG-1 Drug Using Tirzepatide As The Active Ingredient, Calleed Zepbound, For Chronic Weight Management in The Case of Adults With Obesity or Overweight, and with at least One Weight-Related Condition.

Both Mounjaro and Zepbound are produced by the Pharmaceutical Company Eli Lilly.

Now, a New Study Feded by Eli Lilly Reports That People Without Diabetes Can Lose Up To 13% of Their Starting Weight In 6 Months Using Tirzepatide.

The Study Was Recently Published in the Journal Diabetes & Metabolism.

Average 13% Weight Loss On Tirzepatide Over 6 Months

For this study, Refecchers Analyzed Medical Data for About 4,100 People Without A Type 2 Diabetes Diagnosis Listed in The Healthcare Integrated Research Database.

The Average Age of Selected Study Participants Was 46 Years, More than Three-Quarters Were Female, and They had an average body mass index (BMI) of 37.1 kilograms per squar meter (kg/m2).

At the Study’s Conclusion, Scientists Found That Study Participants Lost On Avenge 13% of Their Starting Weight Over 6 Months.

Additionionally, Refers Observed that the rate of continuation for continuous to use Tirzepatide for 6 months or more was 73.8%, which they say is hygher than like other studies have prior prior reported.

Emily R. Hankosky, PHD, senior director of cardiometabolic health, Health Economics and outcomes Research at Eli Lilly & Company, and corresponding author of This Study, confirm for Medical News Today that the participants were Taking Mounjaro as an off-Label Treatment for Weight Management “At The Discretion of Their prescribing Physician.”

Dyslipidemia, Hypertension Most Common Obesity-Related Complications

DURING THES STUDY, REBUERS ALSO reported that about 32% of participants who start tirzepatide had class 3 obesity with a bmi of 40 kg/m2 Or more.

Additionionally, Scientists Found that about 74% of participants had one or more obesity-related complications, While About 51% had two or more complications.

Dyslipidemia was The Most Common Obesity-Related Complication Among Participants, Followed by Hypertension (High Blood Pressure) and Anxiety.

Are the Health Benefits from the drient or the weight loss?

MNT Had the Opportunity To Speak With Mir Ali, MD, A Board-Certified General Surgeon, Bariatric armedon and Medical Director of Memorialcare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, Ca, About This Study.

Ali, Who was not Involved in This Research, Commeable That the Findings Are In Line With What Other Studies Have Shown Regarding The Benefits of Tirzepatide.

“Additional Research Always Helps to define The Patients Who Will Benefit the Most From This Medication, and What Kind of Long Term Effects It Has,” Ali Told us. “And what they’re finding as People are using this medication, they’re seeing the benefits of the weight loss, and it’s hard to separate the effects of the medicine from the weight loss.”

“They’re seeing an improvement in their High Blood Pressure and Other Medical Conditions Associated With Being Overweight, and So There’s a Lot Of Benefits to The Weight Loss,” I have continued. “And This is One of the Most Effective Medications Available Now for This (Weight Loss).”

“As Long As We Learn More About It, There May Be Broader Indications or They Might Appty to Patients Who Are at Lower Weights,” Ali Added.

“Right Now’s Pretty Strict Criteria with the Insurance Companies as To Who They Will Approve It For – They Actually Need To Be In Kind of A Morbid Obesity or Extremely Obese Class to Qualify for This Medication. And it may be more beneficial for People who are not quite so overweight, ”I have suggested.

Potential Side Effects, Cost Considerations for People Without Diabetes

MNT Also Spoke with Jennifer Cheng, Do, Chief of Endocrinology at Hackensack Meridian Jersey Shore University Medical Center in New Jersey, About This Research.

“The Observational Study Confirms What We do See in Clinical Settings, That It is an Effective Agent for Weight Loss,” Cheng, Who Was Likewise not Involved in the Study, Said.

“Many of Our Nondiabetic Patients do the Weight described in the Clinical Study. Zepbound as Well As Semaglutide (Drugs) Have Been Effective For Weight Loss for Patients. The Weight Reduction Also tells Weight Related Complications, Including Hyperlipidemia, Hypertension, Sleep Apnea, (and) Joint Pain. ”

– Jennifer Cheng, do

“It Really You have Been a Game Changer in Terms of Getting Patients to Lose Weight, But It is Im Important That Patients Are Aware of The Side Effects,” She continues.

“It works by Helping to Slow Down the Gut and Helping Patients Feel Full, Faster,“ Cheng Explained. “Patients Eat Less as a result and it Really Helps Them Lose Weight. Patients do Need To Beware They Still Need To Watch Foods That They Eat and Exercise Regularly on Top of Taking Medication. ”

“While it has been studied in patients with diabetes, thhue without diabetes do not the Same Metabolic Derangement as Patients with Diabetes and Can Potentially React Differently in Real World Situations,” She Added.

Like Ali, Though, She Cautioned That: “The Cost of the Medication is Another Consideration that Nondiabetic Patients Should considered. Not all insurances Will cover the medication and the cash price for the medication can be from $ 349- $ 1,298 to months. ”

Cheng Said She Would Like to See Addionional Research to Determine The Long-Term Effects of Tirzepatide On Cardiovascular Disease and Fatty Liver Disease, and potential adverse Effects Such renal unpaid and pancreatitis.

“It was would also determine if the weight loss is substantial to apter stopping medication apter Achieving Weight Loss Goals,” She Added. “More Research is Needed to Help Determine The Advantages and Disadvantages of Medication, But It is Really Promising for Those Who Suffer From Morbid Obesity and Have Weight Related Complications.”